Friday 6 November 2026 Export PTCT’s income statement to Excel — free account

PTC Therapeutics, Inc.

PTC Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.7 billion, up 114.5% from fiscal 2024.

Revenue: +69.6%
EPS: −409.7%
Free cash flow: +90.3%
Total debt: +19.3%

Quarter to September 2026, against a year earlier

Operating cash flow growth 3 yrs

65.55 0.12 −0.18%

Follow PTCT

Alert me

Market cap: $5.5B
P/E: 0.0×
Fwd P/E: 42.2×
Dividend yield: —
F-score: 7/9
Altman Z: 1.86
Beneish M: −1.48
Dividend safety: n/a

Overview

PTC Therapeutics, Inc. (PTCT) P/S ratio

Alert me on P/S ratio

As of 6 November 2026, PTC Therapeutics, Inc. (PTCT) trades at a P/S ratio of 4.7×. Over the past ten years it has ranged from 1.6× (May 2025) to 101× (April 2015); the current reading is higher than 34% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/PTCT/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="PTC Therapeutics, Inc. P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/PTCT/metrics/ps-ratio">PTC Therapeutics, Inc. (PTCT) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	3.5×	(18.81%)
FY2024	4.3×	92.15%
FY2023	2.2×	(42.87%)
FY2022	3.9×	(24.84%)
FY2021	5.2×	(50.76%)
FY2020	10.6×	14.91%
FY2019	9.2×	52.53%
FY2018	6.0×	71.57%
FY2017	3.5×	(23.87%)
FY2016	4.6×	(84.40%)

Period	P/S ratio	Change
Sep 2026	4.7×	(30.28%)
Jun 2026	6.7×	(1.25%)
Mar 2026	6.8×	94.72%
Dec 2025	3.5×	28.96%
43 more quarters	Free account

Against its own ten years

Low 1.6× High 101×

Ten-year median 5.6×

Current reading's percentile 38

Company	P/S ratio
BLTE Belite Bio, Inc. Sponsored ADR compare	n/m
MANE Veradermics Incorporated compare	n/m
IMVT Immunovant, Inc. compare	n/m
KOD Kodiak Sciences Inc. compare	n/m
PTCT PTC Therapeutics, Inc.	4.8×
MIRM Mirum Pharmaceuticals, Inc. compare	9.2×
SRRK Scholar Rock Holding Corporation compare	126×
COGT Cogent Biosciences, Inc. compare	220×
CGON CG Oncology, Inc. compare	919×
Biotechnology industry median	9.2×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

PTC Therapeutics, Inc. (PTCT) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on PTCT

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on PTCT

Stockrow Weekly